stockrowDecoy Therapeutics Inc
DCOY Healthcare Biotechnology
- Revenue
- −84.6%
- EPS
- +94.5%
- Free cash flow
- −212.5%
Quarter to June 2026, against a year earlier
Follow DCOY
Alert me
Decoy Therapeutics Inc (DCOY) Altman Z-score
Decoy Therapeutics Inc's Altman Z-score for fiscal 2021 is 4.56, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2021 | 4.56 | 2.75 |
| FY2020 | 1.81 | 2.38 |
| FY2019 | −0.57 | 0.37 |
| FY2018 | −0.94 | (0.38) |
| FY2017 | −0.56 | (11.10) |
| FY2016 | 10.55 | — |
How fiscal 2021’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.69 | — | 0.82 | |
| Retained earnings / total assets | (0.79) | — | −1.10 | |
| EBIT / total assets | (0.31) | — | −1.04 | |
| Market value of equity / total liabilities | 9.71 | — | 5.83 | |
| Sales / total assets | 0.05 | — | 0.05 | |
| Altman Z-score | Safe zone | 4.56 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 19.09 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| EOCN Eocene Ltd. compare | 26.9× |
| DCOY Decoy Therapeutics Inc | 4.6× |
| AFMDQ Affimed N.V. compare | −9.2× |
| KALA KALA BIO, Inc. compare | −11.2× |
| JUNS Jupiter Neurosciences, Inc. compare | −11.7× |
| BIORQ Biora Therapeutics, Inc. compare | −51.3× |
| BCAB BioAtla, Inc. compare | −70.1× |
| CLDI Calidi Biotherapeutics, Inc. compare | −85.8× |
| NRSN NeuroSense Therapeutics Ltd. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets